SWOG clinical trial number
CTSU/E1A11

Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)

Closed
Phase
Abbreviated Title
Rand PIII Bort/Len/Dex (VRD) vs Carfilzomib/Len/Dex (CRD) w/Limited or Indefinite Maint for New MM
Status Notes
The study was permanently closed to accrual by ECOG ACRIN on January 29, 2019.
Activated
02/01/2014
Closed
07/14/2017
Participants
CTSU

Research committees

Myeloma

Treatment

Dexamethasone CC-5013 (Lenalidomide) Bortezomib Carfilzomib

Other Clinical Trials

S2213
SWOG Clinical Trial Number

A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis

Research Committee(s)
Myeloma
Activated
12/01/2023
3% Accrual
Accrual
3%
Open
Phase
S2209
SWOG Clinical Trial Number

A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma Patients Considered Frail or Ineligible for Stem Cell Transplant Comparing Frontline Regimen Bortezomib-Lenalidomide-Dexamethasone-Lite (VRd-Lite) with Daratumumab-Lenalidomide-Dexamethasone (DRd) Followed by Len+/-Dara (R+/-D) Maintenance

Research Committee(s)
Myeloma
Activated
05/30/2023
15% Accrual
Accrual
15%
Open
Phase
S2005
SWOG Clinical Trial Number

A PHASE II RANDOMIZED STUDY COMPARING IBRUTINIB AND RITUXIMAB VS. VENETOCLAX AND RITUXIMAB IN PREVIOUSLY UNTREATED WALDENSTROM'S MACROGLOBULINEMIA (WM) /LYMPHOPLASMACYTIC LYMPHOMA (LPL)

Research Committee(s)
Myeloma
Activated
06/24/2021
13% Accrual
Accrual
13%
Open
Phase